Senores pharmaceuticals Limited has issued a corporate guarantee of USD 4.1 million to support credit facilities for its wholly-owned US subsidiary. The guarantee was provided to HDFC Bank Limited on March 03, 2026, as part of the company's financial support structure for its international operations.

Corporate Guarantee Details

The pharmaceutical company has extended the guarantee for credit facilities availed by Senores Pharmaceuticals Inc., USA from HDFC Bank Limited. The guarantee covers an amount up to USD 4,100,000 (US Dollars Four Million One Hundred Thousand Only) and represents a significant financial commitment to support the subsidiary's operations.

Regulatory Compliance and Disclosure

The announcement was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has fulfilled its disclosure obligations by providing detailed information about the guarantee arrangement to both BSE Limited and National Stock Exchange of India Limited.

Promoter Interest and Terms

The company has disclosed that promoters and promoter groups have interest in this transaction to the extent of their directorship in the wholly-owned subsidiary. However, the corporate guarantee has been extended at arm's length, ensuring compliance with regulatory requirements for related party transactions.

Financial Impact Assessment

According to the company's disclosure, the corporate guarantee currently has no impact on Senores Pharmaceuticals Limited other than its disclosure in the financial statements as a contingent liability. The guarantee will remain valid until the closure of the credit facilities or the tenure of the credit facilities, whichever occurs earlier.

The corporate guarantee arrangement demonstrates the company's commitment to supporting its international subsidiary's growth and operational requirements while maintaining transparency with stakeholders through proper regulatory disclosures.

Senores Pharmaceuticals Limited has issued a corporate guarantee of USD 1,500,000 to secure additional credit facilities for its US-based material subsidiary. The pharmaceutical company informed stock exchanges about this financial commitment on March 03, 2026, pursuant to regulatory disclosure requirements.

Corporate Guarantee Details

The company has provided the guarantee to HDFC Bank Limited for credit facilities availed by Havix Group Inc. D/B/A Aavis Pharmaceuticals, its material subsidiary based in the USA. This follows an earlier intimation dated July 10, 2025, indicating ongoing financial support for the subsidiary's operations.

Terms and Conditions

The corporate guarantee remains valid until the closure of the credit facilities or their tenure, whichever occurs earlier. The maximum tenure for these credit facilities is set at 10 years, providing long-term financial flexibility for the subsidiary's operations.

The guarantee is structured to secure additional credit facilities, suggesting expansion or enhanced working capital requirements for the US subsidiary's pharmaceutical operations.

Regulatory Compliance and Disclosures

Senores Pharmaceuticals disclosed this transaction under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that promoters and promoter groups have interest in this transaction through their directorship in the material subsidiary, though the guarantee is extended at arm's length.

Financial Impact Assessment

At present, the corporate guarantee has no direct impact on Senores Pharmaceuticals Limited other than its disclosure as a contingent liability in the company's financial statements. This indicates that the subsidiary's credit facilities are performing as expected, with no immediate call on the guarantee anticipated.

The guarantee demonstrates the parent company's confidence in its US subsidiary's business prospects and its commitment to supporting international operations through strategic financial backing.